Abstract 869
Background
Breast cancer contributes to 19-34% of all malignancies- indicating the high disease burden. In view of various socio-economic and cultural reasons, patients usually present at an advanced stage because of lack of awareness and nonexistent breast cancer screening programs in India. Breast self-examination (BSE) is easy cost effective and proven way for early detection.
Methods
Objective: 1. To train women for Breast self-examination in health camps 2. To determine the effectiveness of planned teaching program with respect to BSE Materials & methods: Trained workers and physician prepared a visual aid and short video in local language for breast self examination and spend average 8-12 minutes to educate a group of women. 15:1 random check was done to known their level of understanding and correctness of adopting the method. The participants were observed and supervised by doctors to complete the procedure successfully. The results of Breast Self-Examination were documented.
Results
BSE was successfully trained for a total of 4965 women across 19 camps between 2018-2019. Out of the samples 93% of women understood accurately the right method of BSE and re-traing was felt necessary in 35% as per their perception. Among the camps 165 new cases were reported in participants. Upon physician’s examination 132 suspected participants were referred for mammographic evaluation at medical centers and malignancies were detected in 76 participants, which indicates high impact of such training programs in rural India.
Conclusions
Conclusion: cancer awareness and education programs should be an integral part of health camps to improve women’s health and BSE Is easy to teach and have positive impact for early detection of cancer (the detection rate of 1.5% was quite high especially in the rural areas where medical facilities are poor). If implemented in structured manner BSE is the best and cheapest option for screening women of all ages in Indian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4250 - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
Presenter: Erika Martinelli
Session: Poster Display session 2
Resources:
Abstract
5234 - The ORCHESTRA trial; A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).
Presenter: Lotte Bakkerus
Session: Poster Display session 2
Resources:
Abstract
5294 - EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal cancers
Presenter: Elizabeth Cartwright
Session: Poster Display session 2
Resources:
Abstract
913 - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): subgroup analyses
Presenter: Margaret Tempero
Session: Poster Display session 2
Resources:
Abstract
1668 - FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma : update of the AGEO cohort.
Presenter: Edouard Auclin
Session: Poster Display session 2
Resources:
Abstract
2559 - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT)
Presenter: Hanno Riess
Session: Poster Display session 2
Resources:
Abstract
4897 - Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumor DNA
Presenter: Xiao-ding Liu
Session: Poster Display session 2
Resources:
Abstract
1755 - Evaluation of minimal important difference (MID) for the European Organisation for Research and Treatment of Cancer (EORTC) Pancreatic Cancer Module (PAN26) in patients with surgically resected pancreatic adenocarcinoma
Presenter: Michele Reni
Session: Poster Display session 2
Resources:
Abstract
2876 - Multispectral analysis of lymphocyte complexity in periampullary adenocarcinoma
Presenter: Sebastian Lundgren
Session: Poster Display session 2
Resources:
Abstract
1902 - Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Jae Ho Jeong
Session: Poster Display session 2
Resources:
Abstract